Neck

SkinPen® Precision Wins Prestigious Aesthetics Awards 2024 for "Best Energy Device of the Year"

Retrieved on: 
Thursday, March 21, 2024
Health, Patient, Ageing, Medical device, Dyschromia, Patient satisfaction, Safety, Precision, FDA, Neck

This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.

Key Points: 
  • This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.
  • The Aesthetics Awards are the most prestigious and longest-standing awards ceremony in the UK medical aesthetics specialty.
  • Backed by over 90 clinical studies and extensive clinical data, SkinPen Precision is a game-changer in the aesthetics' landscape.
  • CE Mark – Medical Device Class IIa:
    Medical Purpose: SkinPen Precision Microneedling System is a medical device intended to treat facial acne scars in adults aged 22 years or older.

SkinPen® Precision Wins Prestigious Aesthetics Awards 2024 for "Best Energy Device of the Year"

Retrieved on: 
Thursday, March 21, 2024
Health, Patient, Ageing, Medical device, Dyschromia, Patient satisfaction, Safety, Precision, FDA, Neck

This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.

Key Points: 
  • This prestigious award recognizes the remarkable impact SkinPen Precision has had in advancing healthcare through cutting-edge technology and superior patient outcomes.
  • The Aesthetics Awards are the most prestigious and longest-standing awards ceremony in the UK medical aesthetics specialty.
  • Backed by over 90 clinical studies and extensive clinical data, SkinPen Precision is a game-changer in the aesthetics' landscape.
  • CE Mark – Medical Device Class IIa:
    Medical Purpose: SkinPen Precision Microneedling System is a medical device intended to treat facial acne scars in adults aged 22 years or older.

Flamingo Therapeutics Appoints Leading Medical Oncologist Ezra Cohen, MD to its Board of Directors

Retrieved on: 
Thursday, March 21, 2024
University, Science, AML, UCSD, Associate, HNSCC, Patient, RNA, Acute myeloid leukemia, Cancer, Doctor of Philosophy, MD, MBA, Myelodysplastic syndrome, Therapy, Division, MDS, Neck, Pharmaceutical industry

LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the appointment of Ezra Cohen, MD to its Board of Directors.

Key Points: 
  • LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the appointment of Ezra Cohen, MD to its Board of Directors.
  • Dr. Cohen is a leading medical oncologist and cancer researcher who brings unique and relevant expertise in the development of drugs, especially head and neck cancer, to the Flamingo board.
  • Ezra Cohen, MD currently serves as the Chief Medical Officer of Oncology for Tempus AI.
  • "His expertise in leading globally recognized cancer centers and helping many companies develop successful drugs enhances our Board and we look forward to Ezra's contribution," added Chris Mirabelli, PhD, Chairman of the Board of Flamingo.

THE FRENCH BULLDOG HOLDS ONTO ITS RANKING AS THE MOST POPULAR BREED IN HOUSTON

Retrieved on: 
Wednesday, March 20, 2024
Bulldog, Labrador, Labrador Retriever, Miniature Schnauzer, Family, American Kennel Club, Golden, AKC, Neck, Hunting

NEW YORK, March 20, 2024 /PRNewswire/ -- This year, the French Bulldog took Houston's top spot in the American Kennel Club's (AKC®) 2023 ranking of the most popular AKC-recognized dog breeds in the U.S.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- This year, the French Bulldog took Houston's top spot in the American Kennel Club's (AKC®) 2023 ranking of the most popular AKC-recognized dog breeds in the U.S.
  • The French Bulldog was also recognized as the #1 pup in Miami, FL and Denver, CO.
    Doberman Pinschers have made the top ten in Houston, knocking out Miniature Schnauzers.
  • Meanwhile, the Retrievers have swapped rankings, with the Golden Retriever replacing the Labrador Retriever as #3 most popular breed in 2023.
  • "Doberman Pinschers are an incredibly playful and loving breed," said AKC Executive Secretary Gina DiNardo.

Blossom in Style: Popilush Unveils Exquisite Spring Dress Collection

Retrieved on: 
Wednesday, March 20, 2024
Clavicle, Collection, System, Atmosphere, Neck, Individual, Fashion design

WILLIAMSBURG, Va., March 19, 2024 /PRNewswire/ -- Just in time for the first day of spring, Popilush, pioneers of built-in shapewear apparel, unveiled a fresh spring dress collection showcasing a range of colors.

Key Points: 
  • WILLIAMSBURG, Va., March 19, 2024 /PRNewswire/ -- Just in time for the first day of spring, Popilush, pioneers of built-in shapewear apparel, unveiled a fresh spring dress collection showcasing a range of colors.
  • Among them, dark green echoes the season's subtle charm, while black and lilac pink embrace the imaginative essence of spring.
  • Each dress in this collection is a fusion of practicality and style, featuring distinctive design elements that cater to a variety of tastes and occasions.
  • Popilush has achieved remarkable success, with one dress sold every two minutes, a testament to their popularity and customer satisfaction.

New and Improved Attractions Coming to Dells in 2024: America's tallest waterslide highlights "What's New?" list

Retrieved on: 
Tuesday, March 12, 2024
Fantasy, ATV, ICF, Bed, Weapon, International Crane Foundation, Human, Ice cream, News, Sensation, SpringHill Suites, Cheese, Water, Massage, River, Convention, Kalahari Resorts, Two-seater, Basketball, Golf, Video, AC/DC, Slingshot, Neck, Fast food

WISCONSIN DELLS, Wis., March 12, 2024 /PRNewswire-PRWeb/ -- Wisconsin Dells, recently recognized as one of the best family vacation destinations in the USA by U.S. News, promises an exciting year ahead in 2024. This vibrant destination, known as "The Waterpark Capital of the World!®," is gearing up for the season with a wave of new attractions and improvements, both indoors and out.

Key Points: 
  • Olympus Water & Theme Park will open America's tallest waterslide, "The Rise of Icarus," in summer 2024.
  • Knuckleheads Trampoline Park * Rides * Bowling , a lively indoor amusement park, has added a tiger coaster for tots, with seating for 12.
  • Avid Hotel , the newest pet-friendly lodging property in Wisconsin Dells features amenities including a grab-and-go breakfast, premium coffee, and a 24-hour gym.
  • Pure Sugar Factory , a new candy store on Wisconsin Dells Parkway, offers a delightful experience with classic favorites, oversized treats, and trendy sweets.

Zenith Epigenetics Proudly Supports Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Head, NUT, Aggression, Neck, Quality of life, Health, Zenith, Cell, Prevalence, Prognosis, Patient, Nervous tissue, Clinical trial, NUT carcinoma, Disease, Survival, Sympathetic nervous system, Diagnosis, Metastasis, BET, Carcinoma, Cancer, Pharmaceutical industry

ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
  • Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
  • This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
  • We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Research, AbbVie, Sale, Carcinoma, Lung cancer, Webcast, Anal cancer, Acute myeloid leukemia, Trial of the century, Melanoma, Head, Neck, SCLC, SCCHN, GAAP, ADAM, B7, Therapy, NSCLC, Syndrome, CD123, ID, AACR, Conference, Safety, Enoblituzumab, ImmunoGen, Clinical trial, Half-life, IND, Conference call, Docetaxel, ASCO, Telephone, Cancer, Spacecraft, HEAT, ADAM9, ADC, Society, Patient, Pharmaceutical industry

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024
Head, Neck, Chung, Calreticulin, Vaccine, Immunogenic cell death, Endoplasmic reticulum, ICD, HMGB1, Reactive oxygen species, ATP, Poster, Autophagy, Research, Mouse, Abstract

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.